The new generic versions of both hepatitis C drugs will cost $24,000 for a course of treatment. When Harvoni was introduced to the market in 2014, it was priced at $94,500 a treatment. Epclusa came to the market in 2016 with a list price of $74,760.
Gilead’s generic versions of Epclusa and Harvoni will be launched in Januarythrough a newly created subsidiary, Asegua Therapeutics. The drugs are known as authorized generics, which are cheaper versions of brand-name drugs sold by the original manufacturer.
The brand-name hepatitis C drugs, which cures patients of the illness, remain two of the best-selling pharmaceutical products in history, and helped boost Gilead to a market valuation of nearly $100 billion. However, the hefty price of the drugs also made Gilead the subject of public criticism, with many accusing the pharma giant of greed.
More articles on pharmacy:
PBM lobby selects new chief with government ties: 5 things to know
AbbVie hit with lawsuit over alleged $1.2B kickback scheme
Reputation save: Novartis links employee bonuses to ethical behavior
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
